Prophylaxis of maternal-fetal HIV transmission during labour and delivery
Adult: In HIV-positive pregnant women: 2 mg/kg (diluted up to a Max concentration of 4 mg/mL) via infusion over 1 hour, followed by 1 mg/kg/hour via continuous infusion until the umbilical cord is clamped. For planned caesarean section, start the infusion 3 or 4 hours before the operation.
Intravenous
HIV infection
Adult: For short-term management of patients who are unable to take oral therapy: 1 mg/kg or 2 mg/kg 4 hourly (diluted to a concentration of up to 4 mg/mL) via slow infusion over 1 hour. Continue treatment until oral therapy can be substituted. Dose reduction, dosing interruption, or discontinuation may be required according to the severity of the patient's laboratory parameters (refer to specific product guidelines).
Child: In patients who are unable to take oral therapy: 80-160 mg/m2 6 hourly (diluted to a concentration of up to 4 mg/mL) via slow infusion over 1 hour. Continue treatment until oral therapy can be substituted. Dose reduction, dosing interruption, or discontinuation may be required according to the severity of the patient's laboratory parameters (refer to specific product guidelines).
Neonate: In neonates who are unable to take oral therapy:
Doses are given via infusion over 30 minutes or 1 hour at a concentration of up to 4 mg/mL. Continue treatment until oral therapy can be substituted.
Child: In patients who are unable to take oral therapy: 80-160 mg/m2 6 hourly (diluted to a concentration of up to 4 mg/mL) via slow infusion over 1 hour. Continue treatment until oral therapy can be substituted. Dose reduction, dosing interruption, or discontinuation may be required according to the severity of the patient's laboratory parameters (refer to specific product guidelines).
Neonate: In neonates who are unable to take oral therapy:
Gestational Age | Postnatal Age | Dosage |
<30 weeks | <4 weeks | 1.5 mg/kg 12 hourly. |
4 weeks up to 8-10 weeks | 2.25 mg/kg 12 hourly. | |
>8-10 weeks | 9 mg/kg 12 hourly. | |
30-34 weeks | <2 weeks | 1.5 mg/kg 12 hourly. |
2 weeks up to 6-8 weeks | 2.25 mg/kg 12 hourly. | |
>6-8 weeks | 9 mg/kg 12 hourly. | |
≥35 weeks | <4 weeks | 3 mg/kg 12 hourly. |
≥4 weeks | 9 mg/kg 12 hourly. |
Intravenous
Prophylaxis of maternal-fetal HIV transmission
Neonate:
Doses are given via infusion over 30 minutes or 1 hour at a concentration of up to 4 mg/mL. Start treatment as soon as possible after birth (preferably within 6-12 hours), then adjust the dose based on postnatal age. Treatment may be continued until 4-6 weeks of age depending on the risk assessment.
Gestational Age | Postnatal Age | Dosage |
<30 weeks | <4 weeks | 1.5 mg/kg 12 hourly. |
4-6 weeks | 2.25 mg/kg 12 hourly. | |
30-34 weeks | <2 weeks | 1.5 mg/kg 12 hourly. |
2-6 weeks | 2.25 mg/kg 12 hourly. | |
≥35 weeks | ≤6 weeks | 3 mg/kg 12 hourly. |
Oral
HIV infection
Adult: In combination with other antiretroviral agents: 250 mg or 300 mg bid. Dose reduction, dosing interruption, or discontinuation may be required according to the severity of the patient's laboratory parameters (refer to specific product guidelines).
Child: As cap: Patients weighing 8-13 kg: 100 mg bid; 14-21 kg: 100 mg in the morning, then 200 mg in the evening; 22-30 kg: 200 mg bid; ≥30 kg: Same as adult dose. As tab or oral solution/syrup: Infants ≥4 weeks Patients weighing 4-<9 kg: 12 mg/kg bid or 8 mg/kg tid; 9-<30 kg: 9 mg/kg bid or 6 mg/kg tid; ≥30 kg: Same as adult dose. Alternatively, 240 mg/m2 bid or 160 mg/m2 tid. Doses are given with other antiretroviral agents and must not exceed the recommended adult dose. Dose reduction, dosing interruption, or discontinuation may be required according to the patient's haematological parameters (refer to specific product guidelines).
Neonate: In combination with other antiretroviral agents:
Child: As cap: Patients weighing 8-13 kg: 100 mg bid; 14-21 kg: 100 mg in the morning, then 200 mg in the evening; 22-30 kg: 200 mg bid; ≥30 kg: Same as adult dose. As tab or oral solution/syrup: Infants ≥4 weeks Patients weighing 4-<9 kg: 12 mg/kg bid or 8 mg/kg tid; 9-<30 kg: 9 mg/kg bid or 6 mg/kg tid; ≥30 kg: Same as adult dose. Alternatively, 240 mg/m2 bid or 160 mg/m2 tid. Doses are given with other antiretroviral agents and must not exceed the recommended adult dose. Dose reduction, dosing interruption, or discontinuation may be required according to the patient's haematological parameters (refer to specific product guidelines).
Neonate: In combination with other antiretroviral agents:
Gestational age | Postnatal Age | Dosage |
<30 weeks | <4 weeks | 2 mg/kg 12 hourly. |
4 weeks up to 8-10 weeks | 3 mg/kg 12 hourly. | |
>8-10 weeks | 12 mg/kg 12 hourly. | |
30-34 weeks | <2 weeks | 2 mg/kg 12 hourly. |
2 weeks up to 6-8 weeks | 3 mg/kg 12 hourly. | |
>6-8 weeks | 12 mg/kg 12 hourly. | |
≥35 weeks | <4 weeks | 4 mg/kg 12 hourly. Alternatively, in neonates weighing 2-<3 kg: 10 mg 12 hourly; 3-<4 kg 15 mg 12 hourly; 4-<5 kg: 20 mg 12 hourly. |
≥4 weeks | 12 mg/kg 12 hourly. |
Oral
Prophylaxis of maternal-fetal HIV transmission
Adult: In HIV-positive pregnant women (over 14 weeks of gestation): 100 mg 5 times daily until the beginning of labour. Dose reduction, dosing interruption, or discontinuation may be required according to the severity of the patient's laboratory parameters (refer to specific product guidelines).
Neonate:
Start treatment as soon as possible after birth (preferably within 6-12 hours), then adjust the dose based on postnatal age. Treatment may be continued until 4-6 weeks of age depending on the risk assessment.
Neonate:
Gestational Age | Postnatal Age | Dosage |
<30 weeks | <4 weeks | 2 mg/kg 12 hourly. |
4-6 weeks | 3 mg/kg 12 hourly. | |
30-34 weeks | <2 weeks | 2 mg/kg 12 hourly. |
2-6 weeks | 3 mg/kg 12 hourly. | |
≥35 weeks | ≤6 weeks | 4 mg/kg 12 hourly. Alternatively, for neonates weighing 2-<3 kg: 10 mg 12 hourly; 3-<4 kg 15 mg 12 hourly; 4-<5 kg: 20 mg 12 hourly. |